Recipient tissue cells

Recipient tissue cells represent the collective cellular population of a host organism that receives a therapeutic intervention, such as an organ transplant, hematopoietic stem cell graft, or gene therapy (StatPearls, 2023). These cells are not a single molecular target but rather a biological site where donor-derived immune cells or pharmacological agents interact. In the context of transplantation, recipient tissue cells express Human Leukocyte Antigens (HLA) that can trigger immune responses, leading to graft rejection or Graft-versus-Host Disease (GvHD) (NIH, 2022). Drugs such as calcineurin inhibitors (e.g., Tacrolimus) and antimetabolites (e.g., Mycophenolate) are used to modulate the immune environment surrounding these cells to prevent damage (PubMed, 2021). Monitoring the integrity of recipient tissue cells is often performed using biomarkers like donor-derived cell-free DNA (dd-cfDNA), which indicates cellular injury or rejection (Nature Medicine, 2022). Consequently, while the term describes a broad physiological entity, it is fundamental to the study of pharmacokinetics, toxicology, and transplant immunology.

Other names

Host cellsRecipient cellsTarget tissueHost tissue

Drugs typically target specific molecular pathways (e.g., calcineurin inhibition, mTOR inhibition) within these cells to modulate immune responses or prevent cellular proliferation.